Screening for lung cancer: a systematic review and meta-analysis of controlled trials

Background: Lung cancer is a substantial public health problem in western countries. Previous studies have examined different screening strategies for lung cancer but there have been no published systematic reviews. Methods: A systematic review of controlled trials was conducted to determine whether screening for lung cancer using regular sputum examinations or chest radiography or computed tomography (CT) reduces lung cancer mortality. The primary outcome was lung cancer mortality; secondary outcomes were lung cancer survival and all cause mortality. Results: One non-randomised controlled trial and six randomised controlled trials with a total of 245 610 subjects were included in the review. In all studies the control group received some type of screening. More frequent screening with chest radiography was associated with an 11% relative increase in mortality from lung cancer compared with less frequent screening (RR 1.11, 95% CI 1.00 to 1.23). A non-statistically significant trend to reduced mortality from lung cancer was observed when screening with chest radiography and sputum cytological examination was compared with chest radiography alone (RR 0.88, 95% CI 0.74 to 1.03). Several of the included studies had potential methodological weaknesses. Controlled studies of spiral CT scanning have not been reported. Conclusions: The current evidence does not support screening for lung cancer with chest radiography or sputum cytological examination. Frequent chest radiography might be harmful. Further methodologically rigorous trials are required before any new screening methods are introduced into clinical practice.

[1]  A. Miller Advances in Cancer Screening , 2011, Cancer Treatment and Research.

[2]  P C Prorok,et al.  A national cancer institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers , 2010, Cancer.

[3]  K. Ryanna Integrated PET-CT improves accuracy in staging of NSCLC compared with PET and CT alone , 2003 .

[4]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[5]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[6]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[7]  J. Coebergh,et al.  Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. , 2001, Lung cancer.

[8]  M. Tockman,et al.  Considerations in developing successful, population‐based molecular screening and prevention of lung cancer , 2000, Cancer.

[9]  D. Sugarbaker,et al.  Extent of surgery and survival in early lung carcinoma , 2000, Cancer.

[10]  D. Parkin,et al.  Czech study on lung cancer screening , 2000, Cancer.

[11]  P C Prorok,et al.  Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. , 2000, Journal of the National Cancer Institute.

[12]  W C Black,et al.  Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. , 2000, Journal of the National Cancer Institute.

[13]  Peter C Gøtzsche,et al.  Is screening for breast cancer with mammography justifiable? , 2000, The Lancet.

[14]  H. Faller,et al.  Coping, distress, and survival among patients with lung cancer. , 1999, Archives of general psychiatry.

[15]  O. Miettinen,et al.  Early Lung Cancer Action Project: overall design and findings from baseline screening , 1999, The Lancet.

[16]  P. Prorok,et al.  Reanalysis of the Mayo Lung Project data: the impact of confounding and effect modification , 1999, Journal of medical screening.

[17]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[18]  R. MacCallum,et al.  Stress and immune responses after surgical treatment for regional breast cancer. , 1998, Journal of the National Cancer Institute.

[19]  D. Sugarbaker,et al.  Screening for Lung Cancer: Another Look; A Different View , 1997 .

[20]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[21]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.

[22]  Melamed Mr,et al.  Current status of screening for lung cancer. , 1994 .

[23]  E. Bergstralh,et al.  Screening for lung cancer. A critique of the mayo lung project , 1991, Cancer.

[24]  J. Polak,et al.  Lack of benefit from semi‐annual screening for cancer of the lung: Follow‐up report of a randomized controlled trial on a population of high‐risk males in czechoslovakia , 1990, International journal of cancer.

[25]  J. Wilde A 10 year follow-up of semi-annual screening for early detection of lung cancer in the Erfurt County, GDR. , 1989, The European respiratory journal.

[26]  B J Flehinger,et al.  Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. , 1984, Chest.

[27]  K. Mossman Analysis of risk in computerized tomography and other diagnostic radiology procedures. , 1982, Computerized radiology : official journal of the Computerized Tomography Society.

[28]  G Z Brett,et al.  Earlier diagnosis and survival in lung cancer , 1969, British medical journal.

[29]  G. Byrnes,et al.  Screening for lung cancer. , 2004, The Cochrane database of systematic reviews.

[30]  J. Fox Adult Mortality in Developed Countries: From Description to Explanation , 1996 .

[31]  M. Melamed,et al.  Current status of screening for lung cancer. , 1994, Chest surgery clinics of North America.

[32]  L. Ries,et al.  Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. , 1994, Seminars in surgical oncology.

[33]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[34]  M. Collen,et al.  Multiphasic Health Checkup Evaluation: a 16-year follow-up. , 1986, Journal of chronic diseases.